Danaher Corporation (DHR) is a global science and technology innovator that’s composed of more than 20 operating companies across life sciences, diagnostics, environmental and applied sectors.
The company generated 47% of its revenue from Life Sciences, 33% from Diagnostics and 20% from Environmental and Applied Solutions in 2020. In geographical terms, the company generated 40% of its revenue from North America, 24% from Western Europe, 6% from other developed markets and 30% from high-growth markets.
COVID-19 and Acquisitions Drive Growth
Danaher reported fourth quarter revenue that rose 38.8% to $6.76 billion, beating consensus estimates by $140 million, with non-GAAP earnings of $2.08 per share, beating consensus estimates by 21 cents. The Life Sciences division saw the greatest year-over-year growth due to acquisitions and higher sales from COVID-19 related instruments and consumables.
For the full year, the company expects high-single- to low-double-digit core sales growth with low-double-digit growth including Cytiva. The company also raised its quarterly dividend by 16.7% to $0.21 per share, which represents a 0.39% forward yield. The dividend is payable on April 30, 2021, to shareholders on record as of March 26, 2021, and represents its fourth consecutive year of dividend increases.
Want to keep track of all dividend increases? Subscribe to Dividend.com and have complete access to our exclusive dividend increases list here.
